Reinventing Relevance

New Models for Pharma Engagement with Healthcare Providers in a COVID-19 World

Accenture Healthcare Provider Survey May 2020

COVID-19: What to do Now, What to do Next
With this survey, we sought to understand how healthcare provider operations and needs have changed during COVID-19, and which of these changes will have long-lasting implications for how healthcare providers interact with their patients and with pharma companies.

About the Accenture COVID-19 Healthcare Provider Survey

Participants
The survey participants identified themselves as one of the following healthcare disciplines:

- 25% General Practitioner
- 25% Oncologist
- 25% Immunologist
- 25% Cardiologist

Countries
N = 720
120 participants from each country: USA, UK, France, Germany, China & Japan.

The survey data was collected in May-June 2020, during a time of COVID-19 restrictions in all 6 countries.
About the Audience Profile

**Healthcare setting**

- Resident doctor (Germany): 7%
- Private health institute (France): 9%
- NHS Hospital (UK): 12%
- Hospital Network/IDN/ACO: 18%
- Physician’s Group/Private Practice: 21%
- Independent Hospital: 14%
- Private/Independent Hospital setting: 7%

**Total number of patients treated each year**

Mean: 1,717 patients

- 1,000+: 21%
- 901-1000: 18%
- 801-900: 14%
- 701-800: 12%
- 601-700: 12%
- 501-600: 9%
- 401-500: 7%
- 301-400: 7%

**Practice setting**

- Independent: 68%
- Hospital: 15%
- Private/Independent: 4%
- Hospital Network/IDN/ACO: 3%

Base: Total respondents (720)
About the Audience Profile

**Size of practice**
- Over 30 professional practitioners: 8%
- Between 21 and 30 professional practitioners: 14%
- Between 11 and 20 professional practitioners: 23%
- Between 6 and 10 professional practitioners: 23%
- Between 2 and 5 professional practitioners: 8%
- Single person specialist: 8%

**Location of practice**
- Metropolitan (major city): 57%
- Medium sized city: 36%
- Small town: 6%
- Village/Rural: 1%

Base: Total respondents (720)
COVID-19 has shifted the daily operations of healthcare providers (HCPs) to more virtual interactions with both patients and pharma companies—and with lasting impact. HCPs see great value in more virtual interactions as do patients.

The vast majority of HCPs have seen pharma companies change what they communicate about beyond just product information. Healthcare providers said the services that pharma companies are offering now are of higher value than before COVID-19. Now is the time for pharma companies to redefine their relevance.
Our survey showed a positive shift in how pharma companies engage with healthcare providers, but they have more to do.

**Key Finding #1**
COVID-19 is driving lasting changes in what healthcare providers need and value.

**Key Finding #2**
Pharma companies are starting to redefine their relevance in this new landscape, and healthcare providers are seeing the value.

**Key Finding #3**
Virtual engagement with pharma field reps is here to stay, requiring new ways of creating meaningful connections.
KEY FINDING #1

COVID-19 is driving lasting changes in what HCPs need and value.
Healthcare providers (HCPs) had much fewer in-person patient visits during COVID-19, with most patients deferring or cancelling a treatment, and many asking to be treated remotely.

70% of patients we surveyed said they deferred or cancelled treatment¹.

COVID-19 has altered the daily operations of healthcare providers.

78% of HCPs saw a decrease in the number of patients visiting their practice during COVID-19.

36% of patients asked to have treatment remotely. ¹

¹ How COVID-19 will permanently alter patient behavior. Accenture Survey of 2700 patients
COVID-19 has altered the daily operations of healthcare providers.

50% of general practitioners had a decrease in the daily volume of patients they saw in their practice, but other therapeutic HCPs experienced an even sharper decline:

<table>
<thead>
<tr>
<th>General practitioner</th>
<th>Cardiologist</th>
<th>Immunologist</th>
<th>Oncologist</th>
</tr>
</thead>
<tbody>
<tr>
<td>-50%</td>
<td>-85%</td>
<td>-87%</td>
<td>-90%</td>
</tr>
</tbody>
</table>

32% have been asked to practice outside of their speciality during COVID-19.
Methods and devices that support self-administration and remote monitoring are more valued by healthcare providers now than they were before the pandemic.

During COVID-19

65% of all HCPs said they value self-administration methods for patients (auto-injectors or on-body devices) more than they did pre-COVID-19.

62% of HCPs said they value tools for remote monitoring of their patients at home more than they did prior to COVID-19.

Cardiologists were the most likely to place a higher value on self-administration methods (73%) and tools for remote monitoring (67%) than they did prior to COVID-19.

Nearly 1 in 5 HCPs (19%) expect that asking patients to self-administer more may be a permanent change.

Copyright © 2020 Accenture. All rights reserved.
Healthcare provision in settings such as community centers or retail locations, rather than a physician’s office or hospital, is receiving more interest from patients. Many are looking for care delivery that can take place in their home.

After COVID-19

58% of patients said that after COVID-19 they would be more interested in options for getting treatment without visiting a healthcare provider’s office or a hospital.¹

62% of HCPs believe patients will be more interested in home-administration of treatment, such as by a visiting nurse who comes to their home.

¹ Accenture Patient Survey, May 2020
COVID-19 has generated an appetite for new treatment regimens and new therapies.

Healthcare providers are guiding patients in selecting new therapies and utilizing new devices and apps in order to adapt to the realities of COVID-19.

Patients said 1 in 5 switched therapy as a result of COVID-19.

44% of patients used new devices or apps to help manage conditions during COVID-19 (90% of those wanted to continue using them).1

66% of HCPs have switched some of their patients to a different therapy driven by a fear of side effects or the impact on their risk of COVID-19 (61%).

The timing of administration (44%) and type of administration (41%) were also important considerations in switching patients to a different therapy, especially for oncologists (47% said type of administration was a factor).

1 Accenture Patient Survey, May 2020
Over half cited the following reasons their likelihood increased:

1. a greater ability to monitor patient response (56%)
2. greater access to information on newer products. (55%)
3. having more time to learn about new products and indications (53%)

Healthcare providers are still seeking and some are now more likely to start patients on new treatments.

**88% of HCPs** want companies to continue to launch new products for conditions they treat despite ongoing prevalence of COVID-19.

Nearly 4 in 10 (39%) HCPs report that their likelihood of starting patients on recently launched treatments increased since COVID-19. Immunologists had the highest increase (44%), oncologists were lowest (36%).

1 Accenture Patient Survey, May 2020
Pharma companies are starting to redefine their relevance in this new landscape, and healthcare providers are seeing the value.
Pharma companies are on the path to greater relevance, but they need to move further, faster.

Healthcare providers are seeing pharma companies diversify their communication beyond product information and are finding more value in additional support services from pharma such as education on remote support and digitized patient information.

82% of HCPs say they have seen pharma companies change what they communicate about, delivering not just product information, but support that meets their most pressing needs.

Most HCPs said that these pharma support services are more helpful now than before the COVID-19 crisis:

- Digital patient education: 69%
- Information on how treatment options may change post-COVID-19: 69%
- Education on how to better treat patients remotely: 67%
- Helping patients understand where they can access labs, infusion centers or imaging centers: 65%
- Specific information on helping my patients manage their conditions in light of COVID-19: 65%
- Solutions to help my practice afford and keep stock of therapies: 65%
In the US, affordability programs for patients are seen as particularly helpful.

HCPs indicated that these pharma support services are more helpful now than before the COVID-19 crisis:
Relevance demands quality over quantity.

While new messages from pharma companies were welcome, healthcare providers are also receiving high volumes of digital content that is less relevant and missing the mark.

58% of HCPs agreed that at least one pharmaceutical company has ‘spammed’ them with digital content during COVID-19.

The majority of HCPs maintained the impression that the pharmaceutical companies don’t understand the real impact of COVID-19 on HCPs (57%) and their patients (51%).
Virtual engagement with pharma field reps is here to stay, requiring new ways of creating meaningful connections.
43% of HCPs said that they are currently restricting who can enter the office for professional reasons (no pharmaceutical reps), especially oncologists (46%) and immunologists (44%).

28% of those with restrictions said they believe it is something they may implement permanently and another 44% said they would keep the restrictions “for the foreseeable future.”

Restrictions in access to healthcare facilities will continue for some time—perhaps even permanently.
Sales rep meetings with HCPs have shifted from in-person to virtual meetings.

The majority of HCP meetings with sales reps are now virtual and are expected to stay that way for the foreseeable future.

Before COVID-19, 64% of meetings with pharma sales reps were held in person. During the pandemic, this shifted to 65% of meetings held virtually, consistent across therapeutic areas:
Sales reps are communicating now more than ever, but struggling to be relevant.

The majority of HCPs are interacting with sales reps more than before COVID-19.

However, they want sales reps to have a greater understanding of their needs and expectations.

During COVID-19

61% of HCPs said they communicate with pharma sales reps more now than before COVID-19.

57% of HCPs said pharma sales reps are failing to understand the real impact of COVID-19 on them.
HCPs want the human connection with sales reps in the future, but in different ways.

87% of HCPs want either all virtual or a mix of virtual and in-person meetings even after the pandemic ends.

Only 10% want to go back to pre-COVID norms for in-person meetings.

A shift to a more virtual model means that pharma sales reps have to provide more value to HCPs to get on their schedules.
Virtual doctors will emerge as new influencers in patient treatment and a new focus for pharma rep engagement.

As the move to telehealth gathers pace, new engagement strategies will be needed for virtual doctors.

Pharma will need to identify and engage virtual doctors, who may not currently be part of call planning.

43% of HCPs predict the rise of purely virtual doctors that will influence treatment decisions for their patients, especially in oncology (52%):

- 10% believe that HCPs that treat 100% of their patients virtually will influence treatment for a large portion of their current patients.
- An additional 33% believe those virtual doctors will influence treatment decisions for a small portion of their patients.
What now?

Reimagining pharma’s role

With COVID-19 disruptions to the traditional way of interacting with patients and delivering care, pharma has the opportunity to reinvent its relevance to healthcare providers and rethink its model for engagement.
Now more than ever is the time for pharma to refocus and reinvent its relevance.

Express Empathy.
Recognize and respect the unprecedented human impact of the COVID-19 pandemic today and tomorrow, understanding implications of delayed treatments, patients’ ability to afford treatments, and ongoing mental health challenges.

Rethink Messages.
Review and refresh value propositions to draw out key messages that drive more impact in a post-pandemic world – such as highlighting the ease of administration and ability to maintain adherence without visiting a physical facility.

Expand Support Services that Matter.
Extend practical support to deliver care as close to the patient as possible, from providing clear and easy-to-understand instructions for in-home care to providing details about lab testing locations and care sites so patients can save time and reduce travel to access care.

Create Partnerships.
Build relationships with digital health innovators to deliver new solutions that enable the healthcare provider to continue to support patients to achieve improved adherence to treatment.

Empower the field to engage more relevantly...
Pharma must evolve the field model and seize the opportunity to test bold new ways of thinking and working.

### Evolve field roles to fuel more meaningful customer engagement strategies.
Pharma companies must consider how reps’ unique customer insights and time spent physically off-territory can be repurposed to architecting more personalised and targeted HCP engagement strategies. Selected reps could be assigned new responsibilities alongside their marketing colleagues such as supporting physician journey mapping and helping design the omnichannel experiences that will resonate with their customers best.

### Trust the field on how best to use digital and data to know and engage their customers.
Pharma companies must empower their reps to be the centrepiece of the HCP experience at a time when pressures on capacity and access demand more precision and relevance than ever. Granting reps more autonomy over digital touchpoints - such as enrolling their customers in micro-campaigns aligned to their interests - and equipping reps with novel data to enrich the content and impact of their discussions, can help achieve a new level of personalisation and impact.

### Plan for operational and talent impacts.
New promotional models require changes to the processes and capabilities underpinning them and pre-pandemic ways of working will require revisiting. Understanding and planning for how customers are now targeted, how reps are now incentivized, and how new competencies and skills are now embedded all require a thoughtful and coordinated approach.
Contacts

Brad Michel
Managing Director
Life Science Lead,
North America
brad.michel@accenture.com

Laura Dix
Managing Director
Life Science,
United Kingdom
laura.e.dix@accenture.com

Aman Bajaaj
Managing Director
Life Science Lead,
Growth Markets
aman.bajaaj@accenture.com

Petra Jantzer, PhD
Managing Director
Life Science Lead,
Europe
petra.jantzer@accenture.com
About Accenture

Accenture is a leading global professional services company, providing a broad range of services in strategy and consulting, interactive, technology and operations, with digital capabilities across all of these services. We combine unmatched experience and specialized capabilities across more than 40 industries – powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. With 505,000 people serving clients in more than 120 countries, Accenture brings continuous innovation to help clients improve their performance and create lasting value across their enterprises.

Visit us at www.accenture.com

DISCLAIMER: This document is intended for general informational purposes only and does not take into account the reader’s specific circumstances, and may not reflect the most current developments. Accenture disclaims, to the fullest extent permitted by applicable law, any and all liability for the accuracy and completeness of the information in this presentation and for any acts or omissions made based on such information. Accenture does not provide legal, regulatory, audit, tax or medical advice, and is not a manufacturer of medical devices. Readers are responsible for obtaining such advice from their own legal counsel or other licensed professionals.

Accenture Life Sciences

Patient Inspired. Outcomes Driven.

Accenture’s Life Sciences group is committed to helping our clients make a meaningful impact on patients’ lives by combining new science with leading edge technology to revolutionize how medical treatments are discovered, developed and delivered to people around the world. We provide end-to-end business services as well as broad range of insight-driven services and solutions in strategy, consulting, digital/analytics, technology and operations in all strategic and functional areas—with a strong focus on R&D, Sales & Marketing, Patient Services and the Supply Chain.

We have decades of experiences working with the world’s most successful companies to innovate and improve their performance and across the entire Life Sciences value chain to better serve patients and stakeholders. Accenture’s Life Sciences group connects more than 15,000 skilled professionals in over 50 countries who are personally committed to helping our clients achieve their business objectives and deliver better health and economic outcomes.

Follow us:  

Copyright © 2020 Accenture. All rights reserved.
Appendix
Most countries in this survey reached a peak in new confirmed cases of coronavirus during early April, while new cases in China peaked in February, according to official data. China had government restrictions in place earlier, while the other five countries put various lockdown requirements in place from between late February and mid-March.